CAJ | 학술논문

目的：观察低分子肝素（LMWH）在预防肿瘤化疗期间血栓性疾病的效果。方法将2014年1～10月收治的肺癌、乳腺癌、淋巴瘤、胃癌、结直肠癌等为行化疗的患者分为治疗组和对照组，每组180例。治疗组于化疗开始同时皮下注射低分子肝素，每日1次，连用7～10天；对照组给予常规治疗。观察化疗期间血栓疾病的发病率。结果治疗组的患者血栓性疾病发病率低于对照组患者（P＜0.01）。结论低分子肝素（LMWH）应用于预防肿瘤化疗期间，对于治疗血栓性疾病效果显著。
목적：관찰저분자간소（LMWH）재예방종류화료기간혈전성질병적효과。방법장2014년1～10월수치적폐암、유선암、림파류、위암、결직장암등위행화료적환자분위치료조화대조조，매조180례。치료조우화료개시동시피하주사저분자간소，매일1차，련용7～10천；대조조급여상규치료。관찰화료기간혈전질병적발병솔。결과치료조적환자혈전성질병발병솔저우대조조환자（P＜0.01）。결론저분자간소（LMWH）응용우예방종류화료기간，대우치료혈전성질병효과현저。
Objective To observe the effect of low molecular weight heparin (LMWH) in the prevention of thrombotic diseases during the tumor chemotherapy.MethodsPatients suffering from lung cancer, breast cancer, lymphoma, gastric cancer, colorectal cancer and other chemotherapy patients are divided into treatment group and control group in January 2014 ~ October, 180 cases in each group. The treatment group started at the same time, subcutaneous injection of low molecular heparin in chemotherapy, 1 times a day, for 7 to 10 days, the control group was given routine treatment. To observe the incidence of thrombosis diseases during chemotherapy. ResultsThe treatment group thrombotic disease incidence was signiifcantly lower than that of the control group (P<0.01).Conclusion Low molecular weight heparin (LMWH) has obvious curative effect on prevention of thrombotic disease during chemotherapy, and more safe and reliable.